Weedstocks Newswire Feed
MONTREAL, Aug. 14, 2019 /CNW/ -- Tech veterans join forces with top cannabis and consumer industry investors to create Airgraft, a technology company on a mission to clean up vaporization. Founded in 2018, Airgraft has raised upwards of USD $33 Million in two rounds, while remaining in stealth. Latest round was led by Gotham Green Partners, while first by HumanCo.
"Over the past few years we've witnessed rapid expansion of cannabis delivery methods. Despite being the fastest growing category, vaporization has seen little innovation and consumer awareness of its benefits until now. We are thrilled to invest in Airgraft and their truly forward thinking device that emphasizes responsible use and transparency," stated Jason Adler, Managing Member at GGP.
Airgraft is launching the Airgraft Clean Vaporizer, a smart pod and device system that is shaking up the industry. Made of polished ceramic, Airgraft elegantly conceals a suite of technology features that give control and transparency to users.
"Airgraft is built by a group of passionate people on a mission to do things right. Vapor as a delivery method has been a true game-changer, but it is time to establish much higher standards of responsibility, transparency and quality people expect from modern brands," said Mladen Barbaric, founder and CEO of Airgraft.
The system introduces consumable pod traceability, enabling Airgraft to optimize vapor, remove burn and perfectly serve different plant oils.
HEXO Corp bolsters Ontario foothold with addition of 18 new product listings at the Ontario Cannabis Store
HEXO Corp renforce sa présence en Ontario offrant une gamme de 18 nouveaux produits dans les magasins de l’OCS
TORONTO, Aug. 14, 2019 /CNW/ - Patrick McCutcheon, CEO, MediPharm Labs Inc. (LABS), joined Steven Mills, Head, Company Services, Toronto Stock Exchange and TSX Venture Exchange, to open the market. Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-grade cannabis oil and concentrates and advanced derivative products utilizing cGMP (current Good Manufacturing Practices) designed facility and ISO standard built clean rooms. MediPharm Labs Corp. graduated and commenced trading on Toronto Stock Exchange on July 29, 2019.
SOURCE TMX Group Limited
MediPharm Labs Corp. Opens the Market (CNW Group/TMX Group Limited)
DENVER, CO, Aug. 14, 2019 /CNW/ - HempFusion, Inc. ("HempFusion" or the "Company"), a leading US hemp-based cannabidiol ("CBD") Company with over 30 product SKU's distributed to over 3,400 retailers, is pleased to announce the closing of brokered and non-brokered private placements of a total of 28,800,000 units of the Company (each, a "Unit") at a price of US$1.25 per Unit for gross proceeds of US$36,000,000 (the "Offering"). The brokered portion of the Offering (the "Brokered Private Placement") consisted of the sale of 26,227,650 Units for aggregate gross proceeds of US$32,784,563 and was completed by a syndicate of agents led by Canaccord Genuity Corp. and including Haywood Securities Inc. and PI Financial Corp. (collectively, the "Agents"). Due to demand, the Offering was upsized from US$20,000,000 to US$36,000,000.
The Offering brings the total amount raised this year by HempFusion to US$42,000,000. Together with funds on hand, the Company expects to use the net proceeds of the Offering to:
Each Unit consists of one common share (each, a "Common Share") and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant"). Each Warrant entitles the holder thereof to acquire one common share of the Company (each, a "Warrant Share") at an exercise price (the "Exercise Price") of US$7.00 per Warrant Share, subject to adjustment in certain events, including in instances here the issue price (or deemed issue price) of any equity securities of the Company issued in connection with a going-public transaction is less than US $7.00 per share.
The Warrants are exercisable until the earlier of (i) 36 months from the date (the "Listing Date") the Common Shares are listed on a recognized stock exchange (the "Exchange") and (ii) February 28, 2023. The Company will use its commercially reasonable efforts to list the Warrants on the Exchange following any listing of the Common Shares.
VANCOUVER, Aug. 14, 2019 /CNW/ - Agrios Global Holdings Ltd. (CSE: AGRO) (OTCQB: AGGHF) (FSE: ØSA - WKN-A2N62K) ("Agrios" or the "Company") is pleased to provide an update on its data driven aeroponics platform.
Arable soil scarcity, climate change and higher recurrence of extreme weather events are prompting a shift from outdoor to indoor farming which has eco sustainable methods and less environmental impact. According to GBC, an independent research firm, Agrios, a developer of disruptive technology in the field of agri-tech, is "entering a growth phase" as the global need for agri-tech innovations to support eco-sustainable agronomy increases.
Agrios' data-driven aeroponic technology can be used for any type of indoor cultivation. The Company's aeroponic cultivation facilities are equipped with high precision sensors collecting actionable data on 32 key cultivation metrics. Real time data is sent to Agrios' proprietary software, where data analytics allow for precision cultivation, enabling control of numerous variables, including but not limited to, temperature, humidity, lighting, air quality, water, and nutrients.
Agrios' state-of-the-art aeroponic technologies are an attractive solution for the cannabis cultivation industry as cannabis requires specific conditions to grow well and cultivators must ensure these conditions are optimized. Aeroponics greatly reduces the uncertainty of the growing process and makes the duplication of results from one growth cycle to the next one possible.
A major factor in the production of cannabis is the cost of production and achieving consistent product quality. The table below provides an overview of the costs of several cultivation methods. While the cost to produce is lower in an outdoor grow facility, producers are limited to cultivating between one to two crops annually, where Agrios' aeroponic cultivation clients can harvest an average of five times per annum.
Harvest One Announces Completion of Phase I of the Shoppers Drug Mart & TruTrace Technologies Pilot Program for Validation of Medical Cannabis
VANCOUVER, Aug. 14, 2019 /CNW/ - Harvest One Cannabis Inc. ("Harvest One" or the "Company")(TSX-V: HVT; OTCQX: HRVOF) is pleased to announce that the Company's wholly-owned subsidiary, United Greeneries Ltd. ("United Greeneries"), has completed Phase I of a pilot program (the "Pilot Program") in conjunction with Shoppers Drug Mart ("Shoppers") and TruTrace Technologies Inc. ("TruTrace")(CSE: TTT; OTCQB: TTTSF) designed to increase the transparency and validation of products within the medical cannabis industry.
The Pilot Program uses the StrainSecure™ technology as a master registry for standardized testing, product verification, and quality assurance. Under StrainSecure™, plant testing data and genomic verification for each plant batch is utilized for intellectual property protection and strain validation.
As recently announced by Shoppers, Phase 1 of the Pilot Program has been completed and United Greeneries successfully met all of the requirements of Phase 1 due in part to their early adoption of TruTrace's StrainSecure™ platform and implementation of the Master Genome Strain and Clone Registration Program. Phase 2 is expected to run until late November, followed by full production and implementation.
"Now that we have completed Phase 1 of the Pilot Project, medically-registered patients can have an increased level of confidence in the consumption of our Satipharm branded cannabis through Shoppers" said Grant Froese, CEO of Harvest One. "We are delighted to be a part of this groundbreaking effort that is leading the way towards transparency and traceability within the medical cannabis industry."
"Harvest One has been a strong supporter of our mission and an early adopter of our technology for quite some time," said Robert Galarza, CEO of TruTrace Technologies. "Their entire team views the medical cannabis industry with a great deal of sophistication and foresight; TruTrace is very excited to be working with Harvest One on this program."
VANCOUVER, Aug. 14, 2019 /CNW/ - Vapen MJ Ventures (OTCQX: VAPNF, CSE: VAPN) ("Vapen MJ"), a fully integrated agricultural technology, services and property management company in the regulated cannabis industry, today announced its Vapen CBD subsidiary has executed a strategic partnership with CBD Emporium.
Vapen CBD continues to expand its CBD market penetration with its new strategic partnership with CBD Emporium, the Arizona Headquartered CBD retailer. CBD Emporium provides a broad and deep line of product from the best industry brands and prides itself on offering a highly customer-centric retail experience to guide consumers on their path to health and wellness. CBD Emporium will carry the full-line of Vapen THC-Free, Pharmaceutical Grade, Broad Spectrum CBD Products in all its stores. Products include CBD vape oil, tinctures, edibles, topicals, inhalers and dog treats.
CBD Emporium (cbdemporiumaz.com) currently has nine retail stores located in Arizona. Numerous additional store locations in Arizona and California are planned, with more expansion planned into Nevada, New Mexico and Texas in 2019 and 2020. "Vapen's high quality products are a perfect fit for CBD Emporium's customer base", says John Flanders president of CBD Emporium.
"We're very pleased to partner with CBD Emporium to bring Vapen's high quality, CBD products to their loyal and growing customer base. Consumers associate the CBD Emporium with quality and service," commented Thai Nguyen, Founder and Chief Executive Officer of Vapen MJ Ventures. "This strategic partnership expands our retail and online distribution, allowing us to reach new CBD health and wellness customers and grow our overall market presence."
For more information on this and other Vapen CBD products, visit the website at www. target="_blank" href="https://c212.net/c/link/?t=0&l=en&o=2551135-1&h=2573183712&u=https%3A%2F%2Fvapencbd.com%2F&a=VapenCBD" rel="nofollow">VapenCBD.com or visit the social media pages: Facebook @VapenCBD and Instagram @VapenCBD.
TORONTO, Aug. 14, 2019 /CNW/ - TerrAscend Corp. (CSE: TER; OTCQX: TRSSF) ("TerrAscend" or the "Company"), the first and only cannabis company licensed for sales in Canada, the US, and the EU, today announced that it has completed its first international shipment of dry cannabis flower to its German distribution partner iuvo Therapeutics GmbH ("iuvo"). The shipment was made from TerrAscend's EU GMP certified manufacturing facility in Mississauga, Ontario, Canada. As the Company ships additional product to Germany in partnership with iuvo, it will continue to expand its footprint in Europe and other international markets. The Company looks forward to providing investors with updates on such expansion activities.
TerrAscend and iuvo, respectively were granted an Export Permit by Health Canada, under the Cannabis Act, and an Import Authorization from Germany's Federal Institute for Drugs and Medical Devices, following the issuance of the Company's EU Good Manufacturing Practice ("GMP") certificate on April 29, 2019. TerrAscend is one of only six companies with a GMP certified cannabis facility.
It is expected that the German cannabis market will generate more than $5 billion in revenue by 2025. With more than 30,000 current medical cannabis patients in Germany and upwards of 7,200 kg in annual medical patient consumption, the TerrAscend-iuvo partnership presents an exciting opportunity to fulfill the growing needs of medical cannabis patients in Germany.
"We look forward to bringing TerrAscend's quality products to the German market and working with a partner who is also focused on patient well-being," said Robyn Rabinovich, VP, Cannabis Strategy and Partnerships, "This first shipment solidifies our partnership with iuvo and will allow for ongoing access to high quality medical cannabis products for German patients."
"We are pleased to commence our first shipment to Germany together with our partner TerrAscend." Said Daniel Seidi, Director and Co-Founder of iuvo "In close collaboration we have successfully established a fully EU GMP/GDP licenced supply-chain of our pharmaceuticals. This places us in a unique position to respond to the supply-deficiency within the EU in the interest of the patients in need."
VANCOUVER, Aug. 14, 2019 /CNW/ - Zenabis Global Inc. (TSX:ZENA) ("Zenabis" or the "Company") today announced its financial results for the second quarter ended June 30, 2019. All amounts, unless specified otherwise, are expressed in Canadian dollars.
Key Production Metrics
"We executed at or above plan in the second quarter and, in so doing, continued to make significant progress towards our goal of becoming one of the largest licensed producers of medical and adult-use recreational cannabis in Canada," said Andrew Grieve, Chief Executive Officer of Zenabis. "Notably, the buildout and completion of our growing facilities has progressed generally on time and on budget. The completion of Zenabis Atholville and Zenabis Langley Site A - Part 1 helped us increase our licensed annual production capacity from 10,200 kg of dried cannabis as at March 31, 2019 to 54,000 kg of dried cannabis today. We are on track to achieve our new target of 143,200 kg of annual cannabis cultivation capacity under our existing capital program.
"We achieved meaningful growing process efficiencies during the quarter, such that our dried cannabis output outperformed original design capacity by 35%," continued Mr. Grieve. "Our strength on the cultivation front has given us the confidence to raise our cultivation capacity estimate for Zenabis Atholville by 12,000 kg per annum, from 34,300 kg to 46,300 kg of dried cannabis. We expect our performance ratio in July to exceed 10% of our amended Zenabis Atholville design capacity (more than 40% over original design capacity) based on preliminary results."